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Abstract
Background: Health-related quality of life and survival are two important outcome measures in
cancer research and practice. The aim of this paper is to examine the relationship between quality
of life data and survival time in cancer patients.
Methods: A review was undertaken of all the full publications in the English language biomedical
journals between 1982 and 2008. The search was limited to cancer, and included the combination
of keywords 'quality of life', 'patient reported-outcomes' 'prognostic', 'predictor', 'predictive' and
'survival' that appeared in the titles of the publications. In addition, each study was examined to
ensure that it used multivariate analysis. Purely psychological studies were excluded. A manual
search was also performed to include additional papers of potential interest.
Results:  A total of 451 citations were identified in this rapid and systematic review of the
literature. Of these, 104 citations on the relationship between quality of life and survival were found
to be relevant and were further examined. The findings are summarized under different headings:
heterogeneous samples of cancer patients, lung cancer, breast cancer, gastro-oesophageal cancers,
colorectal cancer, head and neck cancer, melanoma and other cancers. With few exceptions, the
findings showed that quality of life data or some aspects of quality of life measures were significant
independent predictors of survival duration. Global quality of life, functioning domains and
symptom scores - such as appetite loss, fatigue and pain - were the most important indicators,
individually or in combination, for predicting survival times in cancer patients after adjusting for one
or more demographic and known clinical prognostic factors.
Conclusion: This review provides evidence for a positive relationship between quality of life data
or some quality of life measures and the survival duration of cancer patients. Pre-treatment
(baseline) quality of life data appeared to provide the most reliable information for helping clinicians
to establish prognostic criteria for treating their cancer patients. It is recommended that future
studies should use valid instruments, apply sound methodological approaches and adequate
multivariate statistical analyses adjusted for socio-demographic characteristics and known clinical
prognostic factors with a satisfactory validation strategy. This strategy is likely to yield more
accurate and specific quality of life-related prognostic variables for specific cancers.
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Background
Health-related quality of life is now considered an impor-
tant end-point in studies of outcomes in oncology. Stud-
ies of quality of life have several benefits when they show
evidence that the measurements were conducted and
reported appropriately [1]. One benefit is that informa-
tion obtained from such studies can indicate the direc-
tions needed for more efficient treatment of cancer
patients. In addition, it has been shown that quality of life
assessments in cancer patients may contribute to
improved treatment and could even be of prognostic
value [2-7].
However, it is believed that health-related quality of life is
only a single type of patient-reported outcome. Patient-
reported outcome is an 'umbrella term' encompassing any
outcome reported by a patient himself or herself based on
perception of a disease and its treatment, such as health-
related quality of life, functional well-being and satisfac-
tion [8]. This approach is currently receiving more atten-
tion and many believe it could help both physicians and
patients, and even family carers to achieve a better under-
standing of the treatment outcomes of cancer patients and
make appropriate decisions.
Using either term - 'patient-reported outcome' or 'health-
related quality of life' - the evidence compiled suggests
that information provided by cancer patients via quality
of life measures is very helpful for clinical decision-mak-
ing and better patient management. For instance, a recent
review on health-related quality of life assessment in leu-
kaemia randomised controlled trials showed how quality
of life assessments would have added value in supporting
clinical decision-making. The review of 3838 leukaemia
patients indicated that 'imatinib' greatly improved health-
related quality of life compared to 'interferon-based' treat-
ment in chronic myeloid leukaemia patients. The review
concluded that health-related quality of life assessment is
feasible in randomised trials and has the great potential of
providing valuable outcomes to further support clinical
decision-making [9]. As suggested 'the main advantage of
this line of research is that of potentially providing clini-
cians with a more accurate picture of the patient's prog-
nostic profile, hence possibly further improving accuracy
of prognosis and making more tailored treatment deci-
sions' [10].
In addition, since lengthening survival of many or most
cancer patients is considered paramount in every effort at
treatment, the clinical implications of relationship
between quality of life data and survival could be regarded
as very important. Thus, many investigators from both
clinical oncology and health sciences research have begun
demonstrating that health-related quality of life in cancer
patients could be associated with survival duration. In
fact, this group of investigators has sought to justify the
collection of quality of life information, even if only to
assess improved survival as the main outcome in cancer
care. They believed that quality of life data may not only
be helpful in evaluating cancer care outcomes from
patients' or family carers' perspectives but may also, like
clinical information, be prognostic or predictive of sur-
vival duration, thus helping clinicians to reach better deci-
sions on patient management or identify their needs and
decide on possible additional interventions, such as refer-
ral for counselling or psychosocial help and support.
Therefore, biomedical journals have for many years been
publishing reports that focus on the relationship between
quality of life data and survival duration.
The aim of this review was to examine the literature on the
relationship between quality of life data and survival
duration since the topic first appeared in English biomed-
ical journals. The intention was to compile the evidence
so far obtained, contribute to existing knowledge, and
help both researchers and clinicians to achieve a better
profile on the topic, and consequently aid in improving
the quality of life of cancer patients.
Methods
Search engines and time period
A literature search was carried out using MEDLINE,
EMBASE, the Science Citation Index (ISI), the Cumulative
Index to Nursing and Allied Health Literature (CINAHL),
the PsycINFO, the Allied and Complementary Medicine
(AMED) and Global Health databases to assess the exist-
ing knowledge about the relationship between quality of
life data as 'prognostic' or 'predictive' indicators and sur-
vival in cancer patients. The aim was to review all full pub-
lications that appeared in English language biomedical
journals between 1982 and 2008. The year 1982 was cho-
sen because the first study on the relationship between
survival and quality of life data was published in that year.
Definitions
- Health-related quality of life was defined as an individ-
ual's perceived physical, mental and social health status
affected by cancer diagnosis or treatment. This article uses
the terms 'health-related quality of life' and 'quality of life'
interchangeably.
- Health-related quality of life measures (instruments,
questionnaires) were defined as well-established ques-
tionnaires that measure individuals' perceptions of their
own physical, mental and social health status, or some
aspects of their health status resulting from cancer and its
treatment.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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- Health-related quality of life data were defined as the
data collected using valid generic or specific health-related
quality of life measures.
- Predictive or prognostic indicators were defined as any
independent variables (e.g. health-related quality of life
parameters) that can be used to estimate the chance of a
given outcome (e.g. survival duration).
Search strategy
The search strategy was limited to cancer and included the
combination of keywords 'quality of life', 'patient-
reported outcomes' 'prognostic', 'predictor', 'predictive',
and 'survival' in the titles of publications. This provided
the initial database for the review. A manual search also
was performed to include possible additional papers.
Inclusion and exclusion criteria
In addition to publication titles, the literature was exam-
ined to ensure that the study used a quality of life instru-
ment or measured quality of life using proxy indicators,
and applied multivariate analyses for survival adjusted for
one or more known clinical prognostic indicators. Purely
psychological studies were excluded. These were defined
as studies limited to the relationship between one or more
psychological variables, such as fighting spirit, cancer per-
sonality, coping styles, hostility, etc. and survival dura-
tion.
Data synthesis
Data obtained from each single study were synthesized by
providing descriptive tables reporting authors' names,
publication year, study sample, type of cancer (where rel-
evant data were available), instrument used to measure
quality of life, and the main findings or conclusions. The
findings were then sorted and presented chronologically.
Results
Statistics
In total, 451 citations were identified in this systematic
review of the literature. After exclusion of duplicates, the
abstracts of all citations were reviewed. Of these, 104 cita-
tions concerning the relationship between quality of life
and survival were found to be relevant and were further
examined (Figure 1). Here, the major findings are summa-
rized and presented under the following headings.
Early pivotal publications [1982-1989]
During the 1980s, a few papers reported positive relation-
ships between some psychosocial and quality of life
parameters and survival time in cancer patients. The first
paper on this relationship was published in 1982. In that
paper the existing records of 651 patients with broncho-
genic carcinoma were assessed to determine the relation-
ship between survival and four 'non-anatomical' prognostic
indicators: symptomatic history, performance status,
weight loss and age. Adjusting for stage, histological fac-
tors and treatment, the analysis showed that weight loss
and performance status were significantly associated with
survival [11]. In 1985, Cassileth et al. studied 359 cancer
patients and found no association between social and psy-
chological factors and duration of survival or time to
relapse. They did not collect data on health-related quality
of life but concluded that, although these factors may con-
tribute to the initiation of morbidity, the biology of the
disease appears to predominate, overriding the potential
influence of life-style and psychosocial variables once the
disease process has been established [12]. The third paper
on the topic appeared in 1987. This paper compared qual-
ity of life during chemotherapy for advanced breast cancer
between patients receiving intermittent and continuous
treatment strategies. The findings indicated that changes
in the quality of life index, measured by a series of Linear
Analog Self Assessment (LASA) scales for physical well-
being, mood, pain and appetite, were independent prog-
nostic indicators of subsequent survival [13]. Kaasa et al.
also published a paper on the topic in 1989, in which for
inoperable non-small-cell lung cancer they showed that
general symptoms and psychological well-being were the
best predictors of survival duration [14].
Heterogeneous sample of cancer patients
Some studies included a heterogeneous sample of cancer
populations [15-21]. Global quality of life and physical,
social, emotional and cognitive functioning were found to
be independent prognostic indicators of survival.
A number of studies showed that global quality of life or
global health status was associated with survival time [17-
19]. In a study of 253 patients with different cancer diag-
noses, Ringdal et al. [16] performed Cox regression analy-
sis adjusted for clinical, demographic and psychosocial
factors. They found that physical functioning was an inde-
pendent predictor of survival time, but psychosocial cov-
ariates were not. The results are shown in Table 1.
Lung cancer
Relatively more studies have examined the relationship
between quality of life data and survival in lung cancer
patients [11,14,22-45]. These studies included either a
sample of both small-cell and non-small-cell lung cancer
patients, or mostly advanced non-small-cell patients. Two
of these 25 studies reported that the overall quality of life
score was not a predictor of survival [28,44]. In most
instances, baseline overall or global quality of life scores
were independent prognostic indicators of survival dura-
tion. A clinical trial using FACT-L showed that a higher
baseline physical well-being score was not only associated
with a better response to treatment (odds ratio = 1.09; P <
0.001) and lower risk of death (risk ratio 0.95; P < 0.001),Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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A schematic picture of the search strategy limited to cancer patients with indicated keywords in titles of publications (numbers  are frequency of citations) Figure 1
A schematic picture of the search strategy limited to cancer patients with indicated keywords in titles of pub-
lications (numbers are frequency of citations).
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but also showed that the patient-reported health change
during chemotherapy was a significant predictor of clini-
cal outcomes [35]. In contrast, a small-scale study (n = 30,
non-small cell lung cancer) using a similar instrument
showed no association between the change in quality of
life score and survival [31]. In addition, most studies have
shown that pain and appetite loss are independent deter-
minants of overall survival. One found that a 40-point
increase in the pain subscale of the EORTC QLQ-C30 was
associated with a 27% increase in the rate-of-dying hazard
[27]. Similarly, Efficace et al. found that a 10-point wors-
ening in the pain and dysphagia scores in a sample of 391
advanced non-small-cell lung cancer patients resulted in a
hazard ratio of 1.11 and 1.12, equivalent to 11% and 12%
increases in the likelihood of death, respectively [41].
However, psychological distress in lung cancer patients
was also associated with survival duration. A study of 133
lung cancer patients using the Self-rating Depression Scale
(SDS) indicated that item 19 ("I feel that others would be
better off if I were dead") emerged as the most significant
predictor of survival duration [26]. Table 2 summarizes
the results.
Breast cancer
Studies that examined the relationship between quality of
life data and survival in breast cancer patients are pre-
sented in Table 3[13,46-63]. Some showed that baseline
quality of life predicts survival in advanced breast cancer,
but not in early stages of disease [51]. Two recently pub-
lished papers also confirmed that baseline quality of life
was not a prognostic indicator in non-metastatic breast
cancer patients. One of these, using Cox survival analysis,
indicated that neither health-related quality of life nor
psychological status at diagnosis or one year later was
associated with medical outcome in women with early-
stage breast cancer [59]. The other, on a sample of 448
locally advanced (non-metastatic) breast cancer patients,
showed that baseline health-related quality of life param-
eters had no prognostic value [57]. The latter study
reported that the final multivariate model retained
inflammatory breast cancer as the only factor predicting
overall survival, with a hazard ratio of 1.37 (95% CI =
1.02-1.84). However, a study using the Daily Diary Card
to measure quality of life in advanced breast cancer
showed that the instrument afforded accurate prognosis
of the subsequent response to treatment and survival
duration [47]. Similarly, Seidman et al. [48] evaluated
quality of life in two phase-II clinical trials for metastatic
breast cancer and found that the baseline scores of two
validated quality of life instruments independently pre-
dicted overall survival. In addition, some studies have
demonstrated that certain aspects of quality of life data,
Table 1: Studies on relationship between quality of life data and survival in heterogeneous sample of cancer patients
Author(s) Year Sample HRQOL measure(s) Results*
Degner and Sloan [15] 1995 435 ambulatory heterogeneous 
sample of cancer patients 
(including 82 lung cancer)
SDS The single measure of symptom distress 
was a significant predictor of survival in 
lung cancer.
Ringdal et al. [16] 1996 253 heterogeneous sample of cancer 
patients
Physical functioning + 
psychosocial variables
Physical functioning was prognostic factor 
of survival but psychosocial covariates 
were not.
Tamburini et al. [17] 1996 100 terminal cancer patients TIQ Confusion, cognitive status and global 
health status were independent 
prognostic of survival.
Coates et al. [18] 1997 735 advanced malignancies EORTC QLQ-C30 Global QOL and social functioning were 
significantly predictive of survival among 
solid tumor patients, metastatic site.
Dancey et al. [19] 1997 474 heterogeneous population of 
cancer patients
EORTC QLQ-C30 Global QOL was significantly associated 
with survival.
Chang et al. [20] 1998 218 cancers patients 
(colon, breast, ovary or prostate)
MSAS Physical symptom subscale score 
significantly predicted survival.
Lam et al. [21] 2007 170 advanced cancer HDS + ESAS + McGill QOL ESAS score was independent prognostic 
factor for survival.
Abbreviations: EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; ESAS: 
Edmonton Symptom Assessment System; HDS: Hamilton Depression Scale; McGill QOL: McGill quality of Life-single item; MSAS: Memorial 
Symptom Assessment Scale; QOL: quality of life; SDS: Symptom Distress Scale; TIQ: Therapy Impact Questionnaire.
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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Table 2: Studies on relationship between quality of life data and survival in patients with lung cancer
Author(s) Year Sample HRQOL measure(s) Results*
Pater and Loeb [11] 1982 651 bronchogenic carcinoma Symptomatic history, performance 
status, weight loss and age
Weight loss and performance status 
were significantly affected survival.
Kaasa et al. [14] 1989 102 inoperable non-small-cell, 
limited disease
Psychological well-being + disease-
related symptoms + personal 
functioning + everyday activity
General symptoms and psychological 
well-being were the best predictive 
value for survival.
Ganz et al. [22] 1991 40 advanced metastatic lung 
cancer
FLI-C A statistically significant relationship 
was observed between initial 
patient-rated QOL and subsequent 
survival.
Ruckdeschel et al. [23] 1994 438 lung cancer FLI-C Total FLI-C score was significant 
predictor of survival.
Loprinzi et al. [24] 1994 1,115 advanced colorectal or 
lung cancers
A designed patient-completed 
questionnaire
Patients' assessment of their own 
performance status and nutritional 
factors such as appetite, caloric 
intake, or overall food intake were 
prognostic of survival.
Buccheri et al. [25] 1995 128 Lung cancer TIQ The self-estimated difficulty at work 
and doing housework were 
significant independent prognostic 
determinants of survival.
Buccheri et al. [26] 1998 133 Lung cancer SDS Depression was associated with 
survival. Diverse SDS subscales were 
associated with survival.
Herndon et al. [27] 1999 206 advanced non-small-cell 
lung cancer
EORTC QLQ-C30 + Duke-UNC 
Social Support Scale
Pain was a significant predictor of 
survival but overall QOL was not.
Langendijk et al. [28] 2000 198 inoperable non-small-cell 
lung cancer
EORTC QLQ-C30 Global QOL was a strong prognostic 
factor of survival.
Burrows et al. [29] 2000 85 recurrent symptomatic 
malignant pleural effusions
KPS Only the KPS score (score ≥ 70) at 
the time of thoracoscopy was 
predictive of survival. Pleural fluid 
pH, pleural fluid glucose, and EPC 
scores were not as reliable as 
initially reported.
Montazeri et al. [30] 2001 129 lung cancer 
(small and non-small-cell)
NHP + EORTC QLQ-C30 + 
EORTC QLQ-LC13
Baseline global QOL was most 
significant predictor of the length of 
survival.
Auchter et al. [31] 2001 30 non-small cell lung cancer FACT-L (TOI) The change in TOI score was not 
associated with survival. A trend was 
noted for shorter survival with the 
largest negative change in TOI score.
Moinpour et al. [32] 2002 222 advanced non-small-cell FACT-L Total FACT-L score was predictor 
of survival.
Nakahara et al. [33] 2002 179 advanced small- and non-
small cell lung cancer
Tokyo University Egogram 
(measure for mental state)
Mental state was prognostic of 
survival.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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Naughton et al. [34] 2002 70 small-cell lung cancer EORTC QLQ-C30 + CES-D + 
MOS Social Support 
Questionnaire + a sleep quality 
scale
Higher depressive symptoms were 
borderline significant in predicting 
decreased survival.
Eton et al. [35] 2003 573 advanced non-small-cell 
lung cancer
FACT-L + TOI Baseline physical well-being and TOI 
scores predicted either survival 
duration or disease progression 
respectively.
Dharma-Wardene et al. [36] 2004 44 advanced lung cancer FACT-G Baseline FACT-G total score was 
significantly associated with survival.
Nowak et al. [37] 2004 53 pleural mesothelomia EORTC QLQ-C30 + EORTC 
QLQ-LC13
Functional domains and symptom 
scales (fatigue and pain) 
demonstrated predictive validity for 
survival.
Maione et al. [38] 2005 566 advanced non-small-cell 
lung cancer
ADL + IADL + EORTC QOL-C30 
(global QOL)
Baseline global QOL and IADL were 
significant prognostic factors for 
overall survival.
Brown et al. [39] 2005 273 non-small-cell lung cancer EORTC QLQ-C30 + EORTC 
QLQ-LC17 + DDC
Global QOL, role functioning, 
fatigue, appetite loss and 
constipation were prognostic 
indicators of survival.
Martins et al. [40] 2005 41 locally advanced or 
metastatic lung cancer
LCSS Patients' scores on the LCSS 
appetite and fatigue subscales were 
independent predictors of survival.
Efficace et al. [41] 2006 391 advanced non-small-cell 
lung cancer
EORTC QLQ-C30 + EORTC 
QLQ-LC13
Pain, and dysphagia were significant 
prognostic factors for survival.
Sundstrom et al. [42] 2006 301 stag III non-small-cell lung 
cancer
EORTC QLQ-C30 Appetite loss was the most 
significant prognostic factor of 
survival.
Bottomley et al. [43] 2007 250 malignant pleural 
mesothelioma
EORTC QLQ-C30 + EORTC 
QLQ-LC13
Pain, and appetite loss were 
independent prognostic indicators of 
survival.
Fielding and Wong [44] 2007 534 liver and lung cancers FACT-G Global QOL scores did not predict 
survival in liver and lung cancer. 
Physical well-being and appetite 
predicted survival in lung cancer.
Jacot et al. [45] 2008 301 non-small-cell lung cancer LCSS Pretreatment LCSS global symptoms 
score was independent determinant 
of overall survival.
Abbreviations: CES-D: Centre for Epidemiologic Studies-Depression Scale; DDC: Daily Diary Card; EORTC QLQ-C30: European Organization for 
Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-LC13 (or QLQ LC17): EORTC Lung Cancer specific Quality 
of Life Questionnaire (previously containing 17items); FACT-G: Functional Assessment of Cancer Therapy-General module; FACT-L: Functional 
Assessment of Cancer Therapy-Lung module; FLI-C: Functional Living Index-Cancer; IADL: Instrumental Activities of Daily Living; KPS: Karnofsky 
Performance Status; LCSS: Lung Cancer Symptoms Scale; MOS: Medical Outcomes Study; ADL: Activities of Daily Living; NHP: Nottingham Health 
Profile; QOL: quality of life; SDS: Self-rating Depression Scale; TIQ: Therapy Impact Questionnaire; TOI: Trial Outcome Index.
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.
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Table 3: Studies on relationship between quality of life data and survival in patients with breast cancer
Author(s) Year Sample HRQOL measure(s)* Results*
Coates et al. [13] 1987 226 advanced breast cancer LASA scores for physical well-being + 
mood, pain, and appetite 
(as QOL index)
Changes in QOL scores were 
independent prognostic of survival.
Coates et al. [46] 1992 226 advanced breast cancer LASA scores for physical well-being + 
mood, nausea, vomiting, and appetite 
(as QOL index)
Both QOL index and physical well-being 
were independent prognostic factors of 
survival.
Fraser et al. [47] 1993 60 advanced breast cancer DDC + LASA + NHP The DDC provided accurate prognostic 
data regarding subsequent response and 
survival.
Seidman et al. [48] 1995 40 advanced breast cancer MSAS + MSAS-GDI + FLI-C + RMHI + 
BPI + MPAC
Baseline global QOL and distress index 
scores independently predicted the 
overall survival.
Tross et al. [49] 1996 280 early stage breast 
cancer
SCL-90-R No significant predictive effect of the 
level of depression on length of disease-
free and overall survival observed.
Watson et al. [50] 1999 578 early stage breast 
cancer
MAC + CECS + HADS Depression score of the HADS and 
helplessness and hopelessness category 
of the MAC had determinant effect on 
survival.
Coats et al. [51] 2000 227 metastatic and early 
stage breast cancer
Physical well-being + mood, appetite, 
and coping (as QOL index)
Disease-free survival was not significantly 
predicted by QOL scores at baseline or 
by changes in QOL scores. After relapse 
QOL scores were predictive for 
subsequent survival.
Kramer et al. [52] 2000 187 advanced breast cancer EORTC QLQ-C30 Pain was prognostic for survival. 
However, fatigue and emotional 
functioning were significant in backward 
selection model.
Shimozuma et al. [53] 2000 47 advanced or end stage 
breast cancer
QOL-ACD Physical aspects of QOL were 
significantly related to survival. The 
change in scores of both overall QOL 
and the physical aspects of QOL were 
also significant predictors of survival.
Butow et al. [54] 2000 99 metastatic breast cancer Cognitive appraisal of threat + coping + 
psychological adjustment + perceived 
aim of treatment + social support + 
QOL
Minimization was associated with longer 
survival while a better appetite predicted 
shorter duration of survival.
Luoma et al. [55] 2003 279 advanced breast cancer EORTC QLQ-C30 Baseline severe pain was predictive for a 
shorter overall survival. QOL scores had 
no great importance in predicting 
primary clinical endpoints such as time 
to progression or overall survival.
Winer et al. [56] 2004 474 metastatic breast cancer FLI-C + SDS Global QOL and symptom distress 
scores were prognostic for survival.
Efficace et al. [57] 2004 448 nonmetastatic breast 
cancer
EORTC QLQ-C30 Baseline QOL had no prognostic value in 
nonmetastatic breast cancer.
Efficace et al. [58] 2004 275 matastatic breast cancer EORTC QLQ-C30 + QLQ-BR23 Loss of appetite was a significant 
prognostic factor for survival.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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including physical health [46], pain [52,55] and loss of
appetite [58], were significant prognostic indicators of
survival in women with advanced breast cancer. One
study also demonstrated that baseline physical aspects of
quality of life and its changes were related to survival, but
psychological and social aspects were not [53].
Gastro-oesophageal cancers
The findings are summarized in Table 4[64-71]. Studies
have shown that physical functioning was an important
prognostic indicator for survival in this group of cancer
patients. Blazeby et al. [65], using the EORTC core and
specific quality of life measures in their study of 89
oesophageal cancer patients, showed that a 10-point
increase in the physical functioning score corresponded to
a 12% reduction in the likelihood of death at any given
time (95% CI = 4-18%). Recent studies using the EORTC
QLQ-C30 and QLQ-OES18 found that in addition to
physical functioning, symptoms such as fatigue, reflux
and appetite loss were also independent predictors of sur-
vival duration in patients with either gastric or oesopha-
geal cancers [69,70]. Using the same instrument (EORTC
QLQ-C30), a large study of 1080 locally-advanced or met-
astatic oesophago-gastric cancer patients indicated that
the global quality of life during pre-treatment was a pre-
dictor of survival duration [67]. However, a study of 185
localized oesophageal cancer patients reported that,
although fatigue was a predictor of one-year survival, the
global quality of life score was not [71].
Colorectal cancer
Social functioning as measured by the EORTC QLQ-C30,
or health and physical subscales as measured by the Fer-
rans and Powers Quality of Life Index, were shown to be
prognostic for survival in colorectal cancer patients. One
study found that the best model for predicting survival
included diarrhoea, eating disorders, restlessness, and
ability to work and sleep [72]. The results from four clini-
cal trials of 501 locally advanced and metastatic colorectal
cancer patients indicated that one-year survival was 38.3%
and 72.5% for patients with global quality of life scores
below and above the median, respectively [73]. Another
study with a sample of 564 patients with advanced color-
ectal cancer in 10 countries showed that for every 10-
point decrease in social functioning score, as measured by
the EORTC QLQ-C30, there was a 6% increase in the like-
lihood of an earlier death [76]. This study was the first
external validation (on an independent dataset of
patients) of a previously conducted study indicating that
social functioning was an independent prognostic factor
Goodwin et al. [59] 2004 397 early stage breast 
cancer
EORTC QLQ-C30 + POMS + PAIS + 
IES + MACS +ACS + CECS
QOL and psychological status at 
diagnosis and 1 year later were not 
associated with medical outcome.
Watson et al. [60] 2005 578 early stage breast 
cancer
MAC + HADS Helplessness/hopelessness was a 
significant predictor of disease-free 
survival but depression was not.
Lehto et al. [61] 2006 72 localized breast cancer Coping + emotional expression + 
perceived support + life stresses + QOL
Longer survival was predicted by a 
minimizing-related coping while shorter 
survival was predicted by anti-
emotionality, escape coping, and high 
level of perceived support.
Gupta et al. [62] 2007 251 breast carcinoma Ferrans and Powers QLI Baseline patient satisfaction with health 
and physical functioning and overall 
HRQOL were significant prognostic of 
survival.
Groenvold et al. [63] 2007 1588 breast cancer EORTC QLQ-C30 + HADS Emotional functioning was predicted 
overall survival and fatigue was 
independent predictor of recurrence-
free survival.
Abbreviations: ACS: Adjustment to Cancer Scale; BPI: Brief Pain Inventory; CECS: Courtauld Emotional Control Scale; DDC: Daily Dairy Card; 
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; FLIC: Functional Living 
Index-Cancer; HADS: Hospital Anxiety and Depression Scale; IES: Impact of Events Scale; LASA: Linear Analog Self Assessment; MAC: Mental 
Adjustment to Cancer Scale; MPAC: Memorial Pain Assessment Card; MSAS: Memorial Symptom Assessment Scale; MSAS-GDI: Memorial 
Symptom Assessment Scale-Global Distress Index; NHP: Nottingham Health Profile; PAIS: Psychological Adjustment to Illness Scale; POMS: Profile 
of Mood States; QLI: Quality of Life Index; QOL: quality of life; QOL-ACD: Quality of Life Questionnaire for Cancer Patients Treated with 
Anticancer Drugs; RMHI: Rand Mental Health Inventory; SCL-90-R: Symptom Check List-90 items-Revised; SDS: Symptom Distress Scale.
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.
Table 3: Studies on relationship between quality of life data and survival in patients with breast cancer (Continued)Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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of survival [75]. The results are shown in Table 5[24,72-
76].
Head and neck cancer
Since 1998, several papers [77-84] have examined the
relationship between survival and health-related quality
of life in head and neck cancer (Table 6). Overall, four out
of the eight studies showed no clear relationship between
health-related quality of life and survival in head and neck
cancer. A study of 208 head and neck cancer patients
reported that physical functioning, mood and global
quality of life did not predict survival. However, the same
study showed that patients with less than optimal cogni-
tive functioning had a relative risk of recurrence of 1.72
(95% CI = 1.01-2.93) and a relative risk of dying of 1.90
(95% CI = 1.10-3.26) [78]. The authors speculated that
the influence of cognitive functioning on survival in these
patients might be related to the use of alcohol.
In contrast, a recent study of 495 head and neck cancer
patients reported that the SF-36 physical component sum-
mary score and three domains of the HNQOL (pain, eat-
ing and speech) were associated with survival [84]. A
study by Fang et al. using the EORTC QLQ-C30 and
EORTC QLQ-H&N35 showed that, while changes in qual-
ity of life scores in patients with head and neck cancer dur-
ing radiotherapy were not correlated with survival,
baseline fatigue score was a significant predictor of sur-
vival. They reported that an increase of 10 points in the
baseline fatigue score corresponded to a 17% reduction in
the likelihood of survival [79].
Finally, as Mehanna et al. suggested, the relationship
between health-related quality of life and survival in head
and neck cancer patients is currently neither strong nor
proven, although there is some association between
selected psychosocial factors and long-term survival [85].
Table 4: Studies on relationship between quality of life data and survival in patients with gastro-oesophageal cancers
Author(s) Year Sample HRQOL measure(s) Results*
Blazeby et al. [64] 2000 89 oesophageal cancer EORTC QLQ-C30 + Dysphagia 
scale of QLQ-OES24
Physical functioning at baseline was 
significantly associated with survival.
Blazeby et al. [65] 2001 89 oesophageal cancer EORTC QLQ-C30 + Dysphagia 
scale of QLQ-OES24
Physical functioning at baseline was 
significantly associated with survival. 
After treatment, improved emotional 
functioning was significantly related to 
longer survival.
Fang et al. [66] 2004 110 oesophageal squamous cell 
cancer
EORTC QLQ-C30 Pretreatment physical functioning was 
the most significant survival predictor 
while QOL scores during treatment 
were not. After treatment dysphagia 
was the most significant predictor.
Chau et al. [67] 2004 1080 locally advanced or metastatic 
oesophago-gastric cancer
EORTC QLQ-C30 Pretreatment physical and role 
functioning and global QOL predicted 
survival.
Park et al. [68] 2008 164 advanced gastric cancer EORTC QLQ-C30 Social functioning was significant 
prognostic factor for survival.
Bergquist et al. [69] 2008 96 advanced oesophageal cancer EORTC QLQ-C30 + QLQ-
OES18
Physical functioning, fatigue and reflux 
were significant prognostic of survival.
McKernan et al. [70] 2008 152 gastric or oesophageal cancer EORTC QLQ-C30 Appetite loss was significantly 
independent predictor of survival.
Healy et al. [71] 2008 185 localized oesophageal cancer EORTC QLQ-C30 Fatigue score was predictive of 1-year 
survival but global QOL data were not.
Abbreviations: EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; QLQ-OES18 
(previously QLQ-OES24): EORTC Oesophageal Cancer specific Quality of Life Questionnaire; QOL: quality of life.
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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Melanoma
Early studies showed no significant relationship between
survival and social and psychological factors in
melanoma patients [12,86]. However, a number of subse-
quent studies indicated a significant correlation between
quality of life and survival duration. Coates et al., in a
study of 152 patients with metastatic melanoma, found
that overall quality of life, mood, and appetite were signif-
icant predictors of survival [87]. A study of 140 patients
with advanced melanoma [90] found that a score of less
than 75 points in overall quality of life and physical dis-
tress symptoms, as measured by the Rotterdam Symptom
Checklist (RSCL), was associated with hazard ratios of
2.31 (95% CI = 1.09-4-90) and 1.92 (95% CI = 1.10-
3.36), respectively. The results are summarized in Table
7[12,86-91].
Other cancers
Studies of the relationship between quality of life data and
survival have been reported for brain, ovarian, liver, blad-
der and other cancer populations. The findings are pre-
sented in Table 8[44,92-114]. Except for a few studies of
liver, brain and ovarian cancer patients [44,95,112], most
found a significant relationship between quality of life
scores and survival duration in these patients. A study of
468 patients with multiple myeloma, measuring quality
of life by the EORTC QLQ-C30 [94], found that at 12
months follow-up the relative risk of death for a physical
functioning score of 0-20 versus a score of 80-100 was
5.63 (99% CI = 2.76-11.49). A study of 233 patients with
unresectable hepatocellular carcinoma [103] showed that
the hazard ratios for worse appetite score and better phys-
ical and role functioning scores, as measured by the
EORTC QLQ-C30, were 1.07, 0.91 and 0.94, respectively.
However, Mauer et al. in their two studies of brain cancer
[107,108] argued that while classical techniques (regres-
sion analyses) showed a positive relationship between
quality of life data and survival duration, more refined
analyses suggested that baseline health-related quality of
life scores add relatively little to clinical factors for predict-
ing survival.
Discussion
Although a helpful review on this topic was published
recently [115], the present review, to the author's best
knowledge, is the first comprehensive study examining
the prognostic value of quality of life data for survival
time in cancer patients. The review contained 104 studies
and with only a few exceptions, the results in most
instances indicated that health-related quality of life data
or some quality of life measures were significant predic-
tors of survival duration.
The early studies reported here used ad hoc instruments,
while more recent studies used well-validated cancer-spe-
cific quality of life questionnaires. The most recent studies
Table 5: Studies on relationship between quality of life data and survival in patients with colorectal cancer
Author(s) Year Sample HRQOL measure(s) Results*
Loprinzi et al. [24] 1994 1115 advanced colorectal or lung A designed questionnaire Patients' assessment of their own performance 
status and nutritional factors such as appetite, 
caloric intake, or overall food intake were 
prognostic of survival.
Earlam et al. [72] 1996 50 colorectal with liver metastases RSCL + HADS + SIP Diarrhea, eating, restlessness, and ability to work 
and sleep were predictors of survival.
Maisey et al. [73] 2002 501 locally advanced and metastatic 
colorectal
EORTC QLQ-C30 Baseline physical, role, social, emotional functioning, 
global QOL and pain, nausea, dyspnea, and sleep 
difficulties were strong independent predictors of 
survival.
Lis et al. [74] 2006 177 colorectal Ferrans and Powers QLI Health and physical subscale was predictive of 
survival.
Efficace et al. [75] 2006 299 metastatic colorectal EORTC QLQ-C30 Social functioning was a prognostic measure of 
survival beyond a number of previously known 
biomedical parameters.
Efficace et al. [76] 2008 564 metastatic colorectal EORTC QLQ-C30 Social functioning was prognostic factor for survival.
Abbreviations: EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; HADS: 
Hospital and Anxiety Depression Scale; QLI: Quality of Life Index; QOL: quality of life; RSCL: Rotterdam Symptom Checklist; SIP: Sickness Impact 
Profile.
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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supplemented their assessments with site-specific ques-
tionnaires. Overall, 59 different instruments have been
used to measure quality of life in cancer patients [Addi-
tional file 1]. The EORTC QLQ-C30 was found to be the
most widely used cancer-specific instrument, and as the
tables in this review show, the questionnaire often gave
fairly consistent and reliable results. In addition, the sup-
plementary EORTC quality of life modules, such as QLQ-
BR23, QLQ-LC13 and QLQ-BN20, proved very useful
instruments for analysing prognostic indicators, provided
that other methodological requisites were ensured. Such
instruments could even capture information important to
the patients and thus provide better prognostic profiles,
enabling clinicians to manage cancer patients more effec-
tively. However, with regard to instruments listed in the
tables, one should note that some of them were used for a
tailor-specific study, treatment or trial such as the Daily
Diary Card (DDC) and the Auckland Quality of Life Ques-
tionnaire. Evidently some instruments were well-known
generic measures, such as the SF-36, a psychological
instrument such the Hospital Anxiety and Depression
Scale (HADS), and the General Health questionnaire
(GHQ), and/or symptom measures such the Brief Pain
Inventory (BPI), and the Symptom Distress Scale (SDS).
Therefore the information given in the tables was simply
to reflect the variance that existed in the instruments used
and neither to convey their psychometric validity nor
indicate that they were cancer-specific. As such, the results
Table 6: Studies on relationship between quality of life data and survival in patients with head and neck cancer
Author(s) Year Sample HRQOL measure(s) Results*
De Boer [77] 1998 133 head and neck Self-reported psychosocial and 
physical functioning
Patients with higher perceived 
physical abilities were likely to 
survive more and less likely to 
develop a recurrence.
de Graeff et al. [78] 2001 208 head and neck EORTC QLQ-C30 + QLQ-
H&N35 + CES-D
Cognitive functioning was predictor 
of survival while physical 
functioning; mood and global QOL 
were not.
Fang et al. [79] 2004 102 advanced head and neck EORTC QLQ-C30 + EORTC 
QLQ-H&N35
Baseline fatigue was predictive of 
survival while changes in QOL 
scores during treatment was not.
Mehanna and Morton [80] 2006 200 head and neck AQLQ + LSS + GHQ QOL at diagnosis was not significant 
predictor of survival. One year after 
diagnosis poor life satisfaction score 
and pain were significant predictors 
of survival.
Nordgren et al. [81] 2006 89 head and neck EORTC QLQ-C30 Physical functioning was significant 
predictor of survival.
Coyne et al. [82] 2007 1093 locally advanced head and 
neck cancer
Emotional well-being (FACT-G) Emotional functioning was not an 
independent predictor of survival.
Siddiqui et al. [83] 2008 1093 locally advanced head and 
neck cancer
FACT-H&N The FACT-H&N score was 
independently predictive of loco-
regional control but not overall 
survival.
Karvonen-Gutierrez et al. [84] 2008 495 head and neck cancer SF-36, HNQOL The SF-36 physical component 
summary score and three domains 
of the HNQOL (pain, eating and 
speech) were associated with 
survival.
Abbreviations: AQLQ: Auckland Quality of Life Questionnaire; CES-D: Centre for Epidemiologic Studies-Depression Scale; EORTC QLQ-C30: 
European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; EORTC QLQ-H&N35: EORTC Head and Neck 
Cancer specific Quality of Life Questionnaire; FACT-G: Functional Assessment of Cancer Therapy-General module; FACT-H&N: Functional 
Assessment of Cancer Therapy-Head & Neck module; HNQOL: Head and Neck Quality of Life Questionnaire; GHQ: General Health 
Questionnaire; LSS: Life Satisfaction Score; QOL: quality of life; SF-36: 36-item Short Form Health Survey
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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from studies that used ad hoc instruments, a study-specific
questionnaire or only general measures should be inter-
preted with caution.
Many studies reported that the global or the overall qual-
ity of life was a significant independent predictor of sur-
vival. Global quality of life is a straightforward measure,
asking people to evaluate their own health status or qual-
ity of life individually (or in combination). It is argued
that measures such as global quality of life are patient-
rated and thus have the potential to reflect the patient's
well-being better than a physician's observed indicators.
However, it has (for instance) been recommended that
since the global quality of life scale of the EORTC QLQ-
C30 is highly correlated with other scales, it should not be
included in prognostic indicator analyses when other var-
iables from the EORTC QLQ-C30 are used, in order to
achieve model stability [116]. This might explain why a
recent review on the association of psychosocial factors
with survival in head and neck cancer found that the base-
line overall quality of life and depression were not predic-
tors of survival [85]. In addition, when quality of life is
included in prognostic indicator analyses, pre-treatment
(baseline) and follow-up assessments should be distin-
guished. Furthermore, the relationship between baseline
health-related quality of life data and survival refers to dis-
ease-specific characteristics, while follow-up health-
related quality of life data and survival in addition refer to
treatment-specific characteristics. Indeed baseline data are
more often reported to be prognostic because they are
more straightforward to assess. However, collecting fol-
low-up data is a major challenge and should be encour-
aged, since pre-treatment quality of life data were not
prognostic for survival times in some cancers, while
changes in quality of life scores or follow-up data were
usually prognostic in these occasions. More importantly,
tumour type and stage of disease are essential for drawing
conclusions from such findings. In many studies, quality
of life data were prognostic indicators of survival duration
Table 7: Studies on relationship between quality of life data and survival in patients with melanoma
Author(s) Year Sample HRQOL measure(s) Results*
Cassileth et al. [12,86] 1985 and 1988 359 unresectable cancers or 
early stage melanoma or 
breast cancer
Social and psychological factors Social and psychological factors 
individually or in combined did 
not influence the length of 
survival.
Coates et al. [87] 1993 152 metastatic melanoma LASA scales + Spitzer QLI QLI and LASA scores for mood, 
appetite, and overall QOL were 
significant predictors of survival.
Butow et al. [88] 1999 125 metastatic melanoma Cognitive appraisal of threat + 
coping + psychological 
adjustment + perceived aim of 
treatment + social support + 
QOL
Perceived aim of treatment, 
minimization, anger and better 
QOL were independently 
predictive of longer survival.
Brown et al. [89] 2000 426 early stage melanoma 3 single-item LASA scales 
measuring physical well-being, 
mood and perceived effort to 
cope
Shorter survival duration was 
associated with a positive mood 
(On average patients who 
relapsed or died reported using 
more active, distraction or 
avoidant styles of coping).
Chiarion-Sileni et al. [90] 2003 140 advanced melanoma RSCL Baseline overall QOL and the 
physical symptom distress scores 
were significant independent 
prognostic factors for survival.
Lehto et al. [91] 2007 59 localized melanoma Coping with cancer + anger 
expression + perceived social 
support + life stresses + domains 
of QOL
Anger non-expression, 
hopelessness, over-positive 
reporting of QOL reduced 
survival while denial/minimizing 
response to the diagnosis as such 
predicted longer survival.
Abbreviations: LASA: Linear Analog Self Assessment; QLI; Quality of Life Index; QOL: quality of life; RSCL: Rotterdam Symptom Checklist
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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Table 8: Studies on relationship between quality of life data and survival in patients with other cancers
Author(s) Year Sample HRQOL measure(s) Results*
Andrykowski et 
al. [92]
1994 42 leukemia Depressed mood + Functional QOL + 
MAC
Anxious preoccupation and functional QOL 
were independent predictors of survival.
Tannock et al. 
[93]
1996 161 symptomatic 
hormone-resistant 
prostate
EORTC QLQ-C30 + QLQ-PR25 + 
PROSQOLI
Appetite loss, pain, and physical functioning 
were associated with survival.
Wisloff and 
Hjorth [94]
1997 468 multiple myeloma EORTC QLQ-C30 Physical functioning was independent 
prognostic factor of survival.
Meyers et al. 
[95]
2000 80 brain (recurrent 
glioblastoma multiforme 
or anaplastic astrocytoma)
FACT-Br + ADL Measures of QOL and ADL were not 
independently related to survival.
Jerkeman et al. 
[96]
2001 95 aggressive lymphoma EORTC QLQ-C30 Pretreatment global QOL was an 
independent prognostic marker of overall 
survival.
Roychowdury 
et al. [97]
2003 364 locally advanced and 
metastatic bladder
EORTC QLQ-C30 Longer survival was associated with high 
physical functioning, low role functioning and 
no anorexia.
Sehlen et al. 
[98]
2003 153 brain tumors FACT-G The FACT-G sum score was a significant 
predictor of survival.
Collette et al. 
[99]
2004 391 symptomatic 
metastatic hormone-
resistant prostate cancer
EORTC QLQ-C30 Insomnia and appetite loss were significant 
independent predictors of survival.
Monk et al. 
[100]
2005 179 advanced cancer of 
cervix
FACT-G + Cervix subscale + FACT/GOG-
Ntx+ BPI
Baseline FACT-Cx (FACT-G + Cervix 
subscale) scores was associated with survival.
Brown et al. 
[101]
2005 273 brain 
(high grade gloima)
LASA scales (to measure overall QOL)+ 
FACT-Br + Fatigue (SDS) + Sleep (ESS) + 
depression (POMS-SF)+ Mental health 
(MMSE)
Changes in QOL measures over time were 
not found to be associated with survival.
Brown et al. 
[102]
2006 194 brain 
(high grade glioma)
LASA scales (to measure overall QOL)+ 
FACT-Br + Fatigue (SDS) + Sleep (ESS) + 
depression (POMS-SF) + Mental health 
(MMSE)
Fatigue was significant independent predictor 
of survival.
Yeo et al. [103] 2006 233 unresectable 
hepatocellular
EORTC QLQ-C30 Appetite loss, physical and role functioning 
scores were significant predictor of survival.
Lis et al. [104] 2006 55 pancreatic cancer Ferrans and Powers QLI Health and physical subscale was marginally 
significant predictor of survival.
Dubois et al. 
[105]
2006 202 refractory multiple 
myeloma
EORTC QLQ-C30 + QLQ-MY24 + FACIT-
F + FACT/GOG-Ntx
Fatigue was significant predictor of survival.
Sullivan et al. 
[106]
2006 809 metastatic hormon-
refractory prostate
EORTC QLQ-C30 + FACT-P Baseline QOL scores (global QOL, physical, 
role, and social functioning and pain, fatigue 
and appetite loss) were significant predictors 
of survival.
Mauer et al. 
[107]
2007 247 brain 
(anaplastic 
oligodenroglimas)
EORTC QLQ-C30 + EORTC QLQ-BN20 Emotional functioning, communication 
deficit, future uncertainty, and weakness of 
legs were significant prognostic of survival. 
Baseline QOL scores added little to clinical 
factors to predict survival.Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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in patients with solid tumours and advanced diseases, but
not in those with soft tumours and early-stage diseases.
Several measures, such as physical functioning, showed
particularly significant associations with survival duration
in cancer patients. It is argued that physical functioning
might be a surrogate marker for an unrecognized biologi-
cal prognostic indicator, so a causal association between
physical functioning and survival time should not be
inferred [65]. In addition, it is argued that since perform-
ance status and physical functioning are significantly asso-
ciated with each other, in many instances when one
includes both physical functioning and performance sta-
tus in the regression models, the likelihood of finding
inconsistent results can be expected. In other words, in
such circumstances in some studies physical functioning
would emerge as an independent prognostic factor and in
some others performance status or even in certain cases
both might be found prognostic factors for survival dura-
tion. Thus, as indicated earlier, the role of physical func-
tioning and performance status in prognostic studies need
to be evaluated with caution. A recent meta-analysis of the
relationship between baseline quality of life data from the
EORTC clinical trials and survival indicated that physical
functioning was a significant independent prognostic fac-
tor but performance status (as measured by the World
Health Organisation performance status) was not [5],
whereas a study in metastatic kidney cancer patients
reported that both physical functioning and performance
Mauer et al. 
[108]
2007 490 brain 
(new diagnosed 
glioblastoma)
EORTC QLQ-C30 + QLQ-BN20 Cognitive functioning, global health status, 
and social functioning were significant 
prognostic factors of survival. Baseline QOL 
scores added little to clinical factors to 
predict survival.
Fielding and 
Wong [44]
2007 358 liver and lung FACT-G Global QOL scores did not predict survival 
in liver and lung cancer. Physical well-being 
and appetite predicted survival in lung cancer.
Viala et al. [109] 2007 202 multiple myeloma EORTC QLQ-C30, EORTC QLQ-MY24, 
FACIT-F, FACT/GOG-Ntx
14 out of 21 patient-reported outcomes 
were significant predictors of mortality. 
Clinical plus PRO data increased the 
predictive power.
Bonnetain et al. 
[110]
2008 538 advanced 
hepatocellular carcinoma
Spitzer QLI Baseline QOL was independent prognostic 
factor for survival.
Carey et al. 
[111]
2008 244 advanced ovarian 
cancer
EORTC QLQ-C30 Performance status and global QOL scores 
at baseline were prognostic factors for both 
progression-free survival and overall survival.
Gupta et al. 
[112]
2008 90 ovarian cancer Ferrans and Powers QLI No statistically significant prognostic 
association of patient satisfaction with QOL 
was observed with survival.
Robinson et al. 
[113]
2008 86 pancreatic cancer FACIT-F+ FAACT + BPI + SF-36 Fatigue strongly predicted survival.
Strasser-
Weippl and 
Ludwig [114]
2008 92 multiple myeloma EORTC QLQ-C30 Role, emotional, cognitive and social 
functioning but not physical functioning and 
global QOL were found to be independent 
prognostic factors of overall survival.
Abbreviations: ADL: Activities of Daily Living; BPI: Brief Pain Inventory; EORTC QLQ-C30: European Organization for Research and Treatment of 
Cancer Quality of Life Core Questionnaire; EORTC QLQ-BN20: EORTC Brain Cancer specific Quality of Life Questionnaire; EORTC QLQ-
MY24: EORTC Myeloma specific Quality of Life Questionnaire; EORTC QLQ-PR25: EORTC Prostate Cancer specific Quality of Life 
Questionnaire; ESS: Epworth Sleepiness Scale; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue scale; FACT-Br: Functional 
Assessment of Cancer Therapy-Brain module; FACT-G: Functional Assessment of Cancer Therapy-General module; FACT-P: Functional 
Assessment of Chronic Illness Therapy-Prostate module; FAACT: Functional Assessment of Anorexia/Cachexia Therapy; FACT/GOG-Ntx: FACT 
Gynecologic Oncology Group Neurotoxicity scale; LASA: Linear Analog Self Assessment; MAC: Mental Adjustment to Cancer Scale; MMSE: 
Folstein Mini-Mental State Examination; POMS-SF: Profile of Mood State-Short Form; PRO: patient-reported outcomes; PROSQOL: Prostate 
Cancer-Specific Quality-of-Life Instrument; QLI: Quality of Life Index; QOL: quality of life; SDS: Symptom Distress Scale; SF-36: 36-item Short Form 
Health Survey
* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.
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status were correlated with a longer progression-free sur-
vival [117].
Among symptoms, appetite loss, pain and fatigue at base-
line were the most important or strongest independent
predictors of survival in many of the studies on different
cancer populations. One possible explanation is that
these symptoms are very sensitive markers of patient well-
being. In addition, as explained by Efficace et al. [58],
such findings might arise because quality of life measures
in effect mask each other in multivariate analyses, so mak-
ing variables such as appetite loss or pain or fatigue
appear to be the most important or strongest predictors of
survival time. Another possible explanation is that such
symptoms might reflect, for instance, weight loss, which
itself is an important prognostic indicator.
As suggested by Gotay et al. [115], there are several expla-
nations for the association between health-related quality
of life data and survival duration in cancer outcome stud-
ies. They summarized four possible explanations: (i) qual-
ity of life measures include different items and thus
provide more sensitive information than traditional per-
formance status and toxicity measures; (ii) quality of life
data especially those collected at baseline before disease
progression could pick up relevant information earlier
than established clinical prognostic factors; (iii) quality of
life data are markers of patients' behaviour because they
relate to diagnosis, treatment and subsequent outcomes
of the disease; and (iv) quality of life data are markers of
individual characteristics such as personality style and
adapting coping strategies, which affect the disease proc-
ess and outcomes in cancer patients.
In addition, the relationship between measures such as
global quality of life or self-rated health and survival or
mortality might be explained in the context of the body-
mind relationship [118-120]. For instance, a recent publi-
cation on the topic concluded that self-reported health is
a unique indicator of human health status; its origins lie
in a process whereby information from the individual's
body and mind is received, selected, reviewed and sum-
marized and therefore it could predict the most absolute
biological events, such as survival or death [121].
The current review, however, suggests an additional expla-
nation that might be helpful in interpreting the findings
from studies of the relationship between quality of life
data and survival duration. Quality of life data might be
markers of the socio-economic status of cancer patients.
Evidence for a relationship between socio-economic sta-
tus and survival time for many cancers is being compiled
[e.g. see [122-130]]. In this context, a cancer patient's
socio-economic status predicts survival. For instance, can-
cer patients with higher social class would have a better
quality of life [e.g. see [131-134]], and consequently those
who report a better quality of life at baseline assessment
may live longer. Thus it is not surprising that, in addition
to clinical measures, quality of life data are predictive of
survival duration. This hypothesis needs further assess-
ment. In future studies on the relationship between qual-
ity of life data and survival duration, in addition to
biomedical measures, adjustments should be made for
patients' socioeconomic status. It would then remains to
be seen whether health-related quality of life data still act
as significant independent predictors of survival or not.
However, the known clinical measures that most studies
frequently entered into a multivariate model included age
at diagnosis; gender (where necessary); stage (tumour
characteristics); occurrence of metastases (or number of
metastatic sites involved); weight loss; laboratory param-
eters (where necessary); performance status and type of
treatment. It seems that co-morbidity, and measures of
patients' socioeconomic status (for example income, edu-
cation, occupation, living conditions or social class) are
also important to be included in the final model when
one considers assessing the relationship between quality
of life data and survival duration.
Although this review has included studies that examined
the relationship between quality of life data and survival,
it excluded purely psychological studies. There are several
useful studies on association between psychological data
and survival and thus if one wishes to have a better under-
standing on the topic it is necessary to review these papers
as well. For instance, a systematic review of the literature
clearly documented the influence of psychological coping
on survival and recurrence in cancer patients [135]. The
review concluded that there is little consistent evidence
that psychological coping style is important in survival
from or recurrence of cancer. Similarly, a systematic
review of the effect of psychosocial factors on breast can-
cer outcome indicated that, although most studies on the
topic have shown a significant relationship between psy-
chosocial factors and survival, the relevant psychosocial
variables were neither consistently measured across stud-
ies nor, in many cases, consistent in their findings [136].
In contrast, a recent review on the relationship between
stress-related psychosocial factors and survival in cancer
patients indicated that stressful life experiences were
related to poorer cancer survival and higher mortality. It
also suggested that stress-prone personalities or unfavour-
able coping styles, and negative emotional responses or
poor quality of life, were related to poorer cancer survival
and higher mortality [137]. However, some papers that
belonged in principle to the discipline of psychology were
inevitably included in the present review. These papers
usually reported that a measure of quality of life had been
incorporated in the study, but no well-known instruments
were used for the measurements. Contrary to expectation,Health and Quality of Life Outcomes 2009, 7:102 http://www.hqlo.com/content/7/1/102
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these papers found that, in multivariate analyses, condi-
tions such as over-positive reporting of quality of life [91]
or having a better appetite were indicators of shorter sur-
vival [54].
Finally, the inherent limitations and controversial issues
related to studies of relationship between survival and
quality of life data should not be neglected. For example,
many studies reporting on a positive relationship between
survival and quality of life data originate from previously
conducted randomised clinical trials. Although this is the
best-known methodology to evaluate treatments out-
comes, it can also be argued that, since patients in ran-
domised clinical trials have highly selected criteria (e.g. no
associated co-morbidity), one might wonder whether this
association also works in the real world [10]. Perhaps only
by testing this hypothesis in an observational setting
would it be possible to actually verify whether health-
related quality of life parameters have a prognostic value.
In addition, since most evidence on positive relationship
between quality of life data and survival comes from stud-
ies with different patients groups, or studies that used dif-
ferent instruments to measure quality of life, or studies
that applied different statistical methodology (and some-
times even inappropriate statistical analysis), thus cross-
study comparisons are impossible or very complicated,
indicating that current evidence is still inconclusive [138].
With regard to statistical analysis, it is argued that statisti-
cal methodology is crucial in prognostic factor analysis of
health-related quality of life where different statistical
strategies can lead to different findings. Mauer et al. sug-
gest at least two recommendations to increase a substan-
tial accuracy of the prognostic models for relationship
between quality of life data and survival: validation strat-
egy, and added prognostic value of health-related quality
of life factors analysis. They refer to the former as the only
way to avoid over-fitting logistic regression models. These
are regression model that are too dependent on the data
set at hand, making its value on new data doubtful. The
latter strategy, however, refers to computing predictive
accuracy of the final model (including health-related
quality of life data and known clinical prognostic factors)
and comparing it with the predictive accuracy of the
model with known clinical prognostic factors only, using
for instance, C-indexes [138]. More technical details of
Mauer et al. arguments and recommendations can be
found elsewhere [139].
This review included all major search engines in combina-
tion with a manual search. However, since the strategy
was based on keywords in the titles of English language
publications, there is a risk that some relevant papers were
missed. Furthermore, individual reports were not exam-
ined in detail, and so the findings are not all-inclusive.
Bottomley and Efficace have also remarked in their edito-
rial comments that it seems necessary to stress that studies
on the relationship between quality of life data and sur-
vival duration have yielded considerable evidence, but
this is still a relatively novel area of research in oncology
and has a long way to go. They suggested that more
hypothesis-driven prospective studies are needed to pro-
vide robust evidence that health-related quality of life data
and patient-reported outcomes independently predict
survival duration [140].
Conclusion
The studies reported in this review provide evidence for a
positive relationship between quality of life data, or some
aspects of quality of life measures, and the duration of sur-
vival in cancer patients. Pre-treatment (baseline) quality
of life data appeared to provide the most reliable informa-
tion for helping clinicians to establish prognostic criteria
for treating their cancer patients. It is recommended that
future studies should use valid instruments, apply sound
methodological approaches and adequate multivariate
statistical analyses, adjusted for socio-demographic char-
acteristics and known clinical prognostic factors with a
satisfactory validation strategy. This strategy is likely to
yield more accurate and specific quality of life-related
prognostic variables for specific cancers.
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